Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)

<h4>Aims</h4> <p>Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3-LVH trial will test the hypo...

Full description

Bibliographic Details
Main Authors: Pouleur, A-C, Anker, S, Brito, D, Brosteanu, O, Hasenclever, D, Casadei, BS, Edelmann, F, Filippatos, G, Gruson, D, Ikonomidis, I, Lhommel, R, Mahmod, M, Neubauer, SK, Persu, A, Gerber, BL, Piechnik, S, Pieske, B, Pieske-Kraigher, E, Pinto, F, Ponikowski, P, Senni, M, Trochu, J-N, Van Overstraeten, N, Wachter, R, Balligand, J-L
Format: Journal article
Language:English
Published: Wiley 2018

Similar Items